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know that atherosclerosis is a chronic inflammatory dis-
ease of the arterial wall, which in early stage is character-
ized by an endothelial dysfunction. Activation of endo-
thelium leads to the upregulation of adhesion molecules 
and the release of cytokines and chemokines, all of which 
orchestrate leukocyte adhesion and transmigration. 
Among all leukocytes, monocytes are appreciated to be 
the most abundant subset to enter atherosclerotic lesions 
already in early stage and also during the course of lesion 
progression  [1] . Hence, lesion growth and differentia-
tion is primarily sustained by constant monocyte influx 
 [2] . Once monocytes have entered the lesion, they dif-
ferentiate into macrophages and, after uptake of oxi-
dized low-density lipoprotein, into foam cells. Such pro-
cesses could be limited by prevention of continued 
monocyte influx  [3] , premature macrophage apoptosis 
 [4] or egress of such cells  [5] , the latter being a mecha-
nism with debated significance. Thus, recruitment, 
apoptosis and egress of monocytes/macrophages may all 
three serve as targets for therapeutic intervention to lim-
it atherosclerosis.
 This review will summarize the importance of classical 
monocytes in atherogenesis and especially focus on the 
recruitment of those cells to sites of atherosclerosis. Be-
sides the well-described direct mechanisms of adhesion, 
activation and transmigration, we will particularly high-
light the importance of cell to cell interactions exerted by 
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 Abstract 
 Accumulation of classical monocytes is imperative for the 
progression of atherosclerosis. Hence, therapeutic interfer-
ence with mechanisms of lesional monocyte recruitment, 
the primary mechanism controlling macrophage accumula-
tion, may allow for targeting atheroprogression and its clini-
cal complications. Here, we review the important role of clas-
sical monocytes in atheroprogression as well as their routes 
of arterial recruitment. We specifically highlight the role of 
cell adhesion molecules as well as of platelet-derived che-
mokines and neutrophil-borne alarmins. 
 Copyright © 2013 S. Karger AG, Basel 
 Introduction 
 Cardiovascular events are the main cause of morbid-
ity and mortality in western societies. Clinical manifesta-
tions such as myocardial infarction and stroke mainly 
rely on the development and progression of atheroscle-
rosis. Understanding of the pathophysiology of athero-
sclerosis has improved during recent years and we now 
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platelets or neutrophils promoting classical monocyte re-
cruitment in atherosclerosis. However, most of the find-
ings reviewed here stem from animal models making a 
direct translation into the human situation difficult. 
Thus, more research needs to be done to clearly prove if 
such mechanistic assumptions hold true in human patho-
genesis.
 Monocyte and Macrophage Subsets in 
Atherosclerosis 
 About 25 years ago, monocytes were proven to be 
present in both human plaques and lesions obtained from 
animal models  [6, 7] . Direct evidence of the relevance of 
monocytes in atherogenesis could be demonstrated in a 
study where depletion of monocytes reduced plaque for-
mation in rabbits  [8] . However, a more recent study con-
centrated on the question whether depletion of mono-
cytes and macrophages during early or later stages differ-
entially impacts on atherosclerosis  [9] . Although 
employing the diphtheria toxin receptor-mediated con-
ditional cell ablation of all CD11b + cells which may affect 
various myeloid cell subsets, depletion during early stag-
es led to decreased plaque size accompanied by reduced 
macrophage numbers, collagen content and necrotic core 
within the lesion, whereas depletion during later stages 
did not have any of those effects, suggesting the impor-
tance of monocytes during early stages of atherogenesis 
 [9] . The protective effect of monocytes during later stages 
of atherosclerosis may relate to their scavenger function 
clearing apoptotic cells, which protects from inflamma-
tory processes exerted by secondary necrotic cells  [10] .
 Two principal monocyte subsets exist in humans and 
mice  [11, 12] . In humans, monocytes can be differenti-
ated based on the expression of CD14 and CD16  [13, 14] . 
Classical monocytes are defined as CD14 + CD16 – , where-
as non-classical monocytes are CD14 low CD16 + . In mice, 
CD115 + monocyte subsets are discriminated based on 
the expression of lymphocyte antigen 6C (Ly6C). Ly6C + 
monocytes are CX 3 CR1 low CCR2 + and thought to corre-
spond to human classical monocytes. In contrast, murine 
Ly6C – monocytes CX 3 CR1 high CCR2 – are phenotypic 
equivalents of human non-classical monocytes  [15] . 
However, the relative distribution of these subsets among 
total monocyte counts differs between human and mouse 
(90: 10 vs. 50: 50). Nevertheless, they widely exhibit simi-
lar expression patterns for a variety of adhesion mole-
cules, chemokine receptors and other markers indicating 
comparable functional characteristics in both species ( ta-
ble 1 )  [16] . Murine classical monocytes are primarily re-
cruited to inflamed tissue and lymph nodes in vivo, pro-
duce high levels of tumor necrosis factor (TNF)-α and 
interleukin (IL)-1 during infection or tissue damage, and 
therefore, are also termed ‘inflammatory monocytes’  [12, 
17, 18] .
 During the last years, it became evident that 
 hyperlipidemia, an important risk factor for atheroscle-
rosis, induces expansions of classical but not non-clas-
sical monocytes  [19] . Subsequently, apolipoprotein E 
(ApoE) on hematopoietic stem and multipotential pro-
genitor cells (HSPCs) has been identified as part of an 
ABC transporter-mediated cholesterol efflux pathway 
and suppressor of HSPC proliferation, providing a 
mechanistic link between hypercholesterolemia, leuko-
cytosis and the subsequent development of atheroscle-
rotic lesions in mice  [20–22] . Moreover, a more recent 
study describes that cholesterol efflux via ABC trans-
porters prevents from HSPC mobilization and extra-
medullary proliferation  [23] which might be of high 
 interest as the spleen has previously been identified 
to  be a reservoir of classical monocytes which can be 
readily mobilized during inflammation  [24] . In accor-
dance with this finding, splenectomized mice failed to 
develop monocytosis under acute inflammatory condi-
Table 1.  Adhesion molecules, chemokine receptors and other 
markers in humans and mice
Subset  Human Mouse
cla ssical non-classical classical non-classical
Adhesion molecules
CD62L ++ – ++ –
PSGL-1 ++ + ++ +
CD44 n.d. n.d. + +
CD11a n.d. n.d. + ++
CD11b ++ ++ ++ ++
CD49b n.d. n.d. + –
Chemokine receptors
CCR1 + – ++ +
CCR2 ++ – ++ +
CCR5 + + + +
CX3CR1 + ++ + ++
Others
F4/80 n.d. n.d. + +
Gr1 n.d. n.d. + –
CD115 ++ ++ ++ ++
MHCII + ++ – –
CD68 ++ ++ + +
n.d. = Not defined.
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tions  [24] , and splenic monocytes give rise to lesional 
macrophages  [25] and infiltrate the myocardium after 
infarction  [26] .
 Circulating classical monocyte counts directly corre-
late with the extent of atherosclerotic lesion formation 
 [19, 27, 28] , and hence, mechanisms maintaining mono-
cyte homeostasis are of interest in the discussion of arte-
rial monocyte accumulation. By employing a combina-
tory depletion and resubstitution strategy for whole leu-
kocytes and classical monocytes, we could recently 
demonstrate that classical rather than non-classical 
monocytes drive atheroprogression  [28] . Homeostasis of 
classical monocytes is tightly regulated by the MCP-1/
CCR2 axis with mice deficient in CCR2 having very much 
reduced counts of circulating classical monocytes. Thus, 
under acute inflammatory conditions, murine classical 
monocytes are massively mobilized from bone marrow in 
a CCL2/CCR2- and CCL7/CCR2-dependent fashion  [29, 
30] . However, in the context of atherosclerosis, this axis 
seems to be of minor relevance as plasma concentrations 
of CCL2 and CCL7 do not increase in Apoe –/– mice fed a 
high-fat diet  [28] . Additionally, although mice deficient 
in CCR2 display a markedly reduced number of circulat-
ing classical monocytes under steady-state conditions, 
monocyte counts still increase under hypercholesterol-
emia  [28] . Although, the before mentioned findings ex-
clusively stem from mouse models, the importance of hu-
man monocyte subsets has further been proved in recent 
studies, clearly indicating a correlation between classical 
monocyte counts and the occurrence of cardiovascular 
events. Hence, classical rather than non-classical mono-
cytes have been identified as possible prediction markers 
in human [31, 32].
 Once recruited to sites of inflammation, classical 
monocytes are supposed to preferentially differentiate to 
M1 macrophages or TNF-α-producing Tip-DCs  [17] . In 
contrast, extravasated non-classical monocytes initiate a 
typical macrophage differentiation program by expres-
sion and upregulation of markers characteristic for alter-
natively activated macrophages  [33] , also termed ‘M2-
like macrophages’  [34, 35] . However, such simplified 
classification seems not to be applicable in atherosclerosis 
as M1 or M2 macrophages within the lesion could not be 
proved to descend from the one or the other monocyte 
subset, so far. M1 as well as M2 macrophages are both 
detectable within human and murine atherosclerotic le-
sion sites  [36, 37] . Of note, based on their inflammatory 
characteristics, M1 macrophages are expected to promote 
atherosclerosis development, while M2 macrophages in 
general may be considered to be protective in this regard 
 [38] . Both subsets have been shown to be able to undergo 
a switch from one macrophage phenotype to the other 
depending on the stage-dependent environment within 
atherosclerotic lesions  [36] . Thus, suggesting a preferen-
tial role of the cytokine microenvironment within the le-
sion rather than the cellular origin in M1-macrophage 
polarization [39]. However, the specific cytokine milieu 
might be primarily sustained by TNFα and IL-1-secreting 
classical monocytes continuously infiltrating the lesion. 
This is further corroborated by a recent finding that IL-13 
decreases vascular endothelial cell adhesion molecule 1 
(VCAM-1)-mediated recruitment of classical monocytes 
which not only resulted in reduced macrophage accumu-
lation but also induced alternatively activated M2 macro-
phages  [40] . Furthermore, depletion of classical but not 
non-classical monocytes increased the fraction of M2 
macrophages within lesions from aortic roots (unpub-
lished data), indicating that classical monocytes secrete 
cytokines to suppress polarization towards alternatively 
activated M2 macrophages. In human, macrophage het-
erogeneity in atherosclerosis was demonstrated early on, 
characterizing centrally located macrophages as being 
more mature and differentiated compared to their coun-
terparts within the superficial layer [41]. Although spe-
cific markers for M1 as well as M2 macrophages are pres-
ent within human carotid atherosclerotic lesions [37], 
functional associations are rare. However, CD163 a 
marker typical for M2 macrophages could be related to 
intra-plaque hemorrhage [42]. This finding was further 
corroborated by another study demonstrating that M1 
macrophages dominate the rupture-prone shoulder of 
atherosclerotic plaques whereas M2 specific markers 
were detectable in vascular adventitial tissue and stable 
plaques [43]. All of these findings highlight the impor-
tance of classical monocytes in atheroprogression. There-
fore, a detailed understanding of classical monocyte re-
cruitment to atherosclerotic lesions is essential for the 
identification of new therapeutic options.
 Monocyte Recruitment – The Role of Adhesion 
Molecules and Chemokines 
 The classical leukocyte adhesion cascade is character-
ized by rolling, which is mediated by selectins, by activa-
tion, which is mediated by chemokines, and by integrin-
mediated arrest  [44] . However, progress has been made 
in defining additional steps such as capture (or tethering), 
slow rolling, adhesion strengthening and spreading, in-
travascular crawling, and paracellular and transcellular 
D
ow
nl
oa
de
d 
by
: 
UB
 d
er
 L
M
U 
M
ün
ch
en
   
   
   
   
   
   
   
   
   
   
   
   
 
12
9.
18
7.
25
4.
47
 - 
10
/2
0/
20
14
 2
:3
7:
40
 P
M
 Monocyte Recruitment in Atherosclerosis  J Innate Immun 2013;5:358–366 
DOI: 10.1159/000348795
361
transmigration, which is mediated by integrins and junc-
tional molecules ( fig.  1 ) [44] . P-selectin, for example, 
which is expressed on monocytes, neutrophils and lym-
phocytes  [15] , is upregulated in human atherosclerotic 
plaques whereas it is not expressed on non-inflamed en-
dothelium  [45] . Mice deficient in P-selectin displayed 
lower macrophage numbers in the plaque and developed 
smaller atherosclerotic lesions  [46] indicating reduced in-
flux of classical monocytes. Similar effects on plaque de-
velopment were observed in E-selectin-deficient mice 
 [47] . The involvement of selectins and cell adhesion mol-
ecules in general has traditionally been investigated for 
the whole monocyte population, whereas recent data in-
dicate distinct engagement patterns of these receptors for 
monocyte subsets  [15] . For instance, P-selectin glycopro-
tein ligand 1 (PSGL-1), the high-affinity counter-receptor 
for P-selectin, has been demonstrated to be expressed at 
higher levels on classical monocytes and is hence crucial-
ly involved in the interaction of these cells with the ath-
erosclerotic endothelium  [48] . Furthermore, classical 
monocytes express higher amounts of CD62L and CD49b 
as compared to their non-classical counterparts ( table 1 ) 
 [15] . Thus, one may speculate that these molecules pri-
marily contribute to the accumulation of classical rather 
than non-classical monocytes. Monocytes express both 
α 4 - as well as β 2 -integrins interacting with endothelial 
VCAM-1 and ICAM-1, respectively. Absence of either 
ICAM-1 or β 2 -integrins or both led to reduction in aortic 
root lesion sizes  [49] . Similarly, VCAM-1-dependent 
mechanisms were found to be crucial in early stages of 
CCL5, CXCL4
NeutrophilClassical monocyte Endothelial cellPlatelet Macrophage Foam cell
LL37
Rolling and activation
PSGL-1
P-selectin
L-selectin
E-selectin
CCR5
CCR1
Arrest
α4-integrins
α4-integrins
α4-integrins
β2-integrins
ICAM-1 VCAM-1 JAM-C
β2-integrins
β2-integrins
β2-integrins
JAM-A
oxLDL
ICAM-1VCAM-1
Rolling and
activation
Arrest
TNF-α
IL-1β
oxLDL
CCL5
Transmigration Deposition
PLA
CCR5
CCR1
CCR2
CCL2, CCL5,
CXCL4
PSGL-1
P-selectin
PSGL-1
IL-6
IL-6Rα LL37
IL-6
IL-6Rα-IL-6
FPR1/2
CCL2
CCR2
gp130 VCAM-1
M1
a b c
 Fig. 1. Recruitment of classical monocytes in atherosclerosis. 
 a  Rolling of classical monocytes along atherosclerotic endothelium 
is primarily mediated by selectins and PSGL-1 but also by the in-
teraction of α 4 - and β 2 -integrins with ICAM-1 and VCAM-1. In-
tegrins on the cell surface of classical monocytes are further acti-
vated by binding of chemokines such as CCL5 to its receptors 
CCR1 and CCR5, thereby promoting firm adhesion of cells. Once 
emigrated, classical monocytes become macrophages and provide 
a cytokine milieu favoring M1-like macrophage polarization and, 
after uptake of oxidized low-density lipoprotein (oxLDL), trans-
form into foam cells.  b Platelets and classical monocytes can form 
aggregates (PLAs), thereby promoting tethering and slow rolling 
along the endothelium. Activated platelets secret several chemo-
kines which are either deposited onto the endothelium or can di-
rectly activate classical monocytes via their respective receptors. 
 c   By releasing azurocidin (LL37/CRAMP), neutrophils mediate 
adhesion of classical monocytes to atherosclerotic endothelium via 
FPRs (FPR1/2). Another proposed mechanism is the shedding of 
IL-6Rα from neutrophils which forms complexes with IL-6 re-
leased from either macrophages or endothelial cells, thus inducing 
release of CCL2 and upregulation of VCAM-1 on endothelial cells. 
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atherosclerosis  [50] . Hence, inhibition of α 4 -integrin and 
ICAM-1 markedly attenuates lesional macrophage accu-
mulation in atherosclerotic plaques in Apoe –/– mice  [51] . 
The junctional adhesion molecule (JAM)-C is known to 
be a counter receptor for CD11b/CD18, thereby promot-
ing leukocyte adhesion. JAM-C is highly expressed in ath-
erosclerotic vessels  [52] . Exposure of endothelial cell 
monolayers to oxidized low-density lipoprotein induces 
reorganization from interendothelial junctions towards 
the luminal side of the endothelium, thus promoting leu-
kocyte adhesion  [52] . In line, blockade of JAM-C reduces 
monocyte adhesion in vivo  [53] . Similarly, JAM-A binds 
to CD11b/CD18  [54] and promotes monocyte adhesion 
under atherosclerotic conditions  [55] . Interfering with 
chemokine-dependent activation has been widely de-
scribed to protect from atherosclerosis  [56, 57] . CCL5 for 
example, as well as other chemokines, have been shown 
to be deposited onto inflamed endothelium, thereby trig-
gering the arrest of rolling monocytes  [58, 59] . In general, 
leukocyte integrin affinity can be modulated in a chemo-
kine and G-protein-coupled receptor-dependent manner 
 [60, 61] . Besides a possible role of chemokine receptors in 
cell endurance  [4] , inflammatory monocytes were depict-
ed to emigrate into atherosclerotic lesions by utilizing 
CX 3 CR1, CCR2 and CCR5  [62] . However, by dissecting 
chemokine-related effects on myeloid cell hemostasis 
from direct impact on recruitment, we recently demon-
strated that adhesion and recruitment of classical mono-
cytes to atherosclerotic lesions relies on CCR1 and CCR5 
but is not dependent on CX 3 CR1 or CCR2  [28] .
 Monocyte-Platelet Interplay in Atherosclerosis 
 In addition to their well-appreciated role in coagula-
tion, the importance of activated platelets in the initia-
tion of atherosclerotic lesion formation evolved over the 
last decade and is now widely accepted  [63, 64] . The im-
portance of platelets was further proven in a study where 
repeated injection of activated platelets led to exacerbat-
ed atherosclerosis in hyperlipidemic mice  [59] . Two 
principal mechanisms have been proposed by which 
platelets might trigger monocyte recruitment during ath-
erosclerosis development. First, activated platelets have 
been described to form aggregates with leukocytes (plate-
let-leukocyte aggregate, PLA), especially monocytes, 
thereby triggering inflammatory reactions of the arterial 
wall and endothelial cells  [64–66] . The clinical relevance 
of those aggregates was evidenced in acute coronary syn-
drome  [67] . Through P-selectin, platelets bind to PSGL-
1 and thereby form multicellular aggregates, which can 
promote the release of chemokines CCL2 and CCL5 and 
cytokines such as IL-1β to further activate leukocytes  [59, 
64] . Additionally, physical interaction of platelets and 
leukocytes induces tethering and rolling of PLAs on en-
dothelial cells with higher avidity compared to non-ag-
gregated leukocytes enhancing endothelial activation 
and leukocyte transmigration  [65, 68] ( fig. 1 ).
 A second mechanism of platelet-mediated monocyte 
recruitment involves the release of a multitude of pre-
formed proteins from platelet α-granules. Secreted pro-
teins include chemokines such as CXCL4 (PF4), CCL5 
(RANTES), CXCL7 (CTAP-III) and CXCL12 (SDF1) 
 [64] that can easily be deposited on activated endothe-
lium, thereby triggering monocyte adhesion  [58] . Depo-
sition of CCL5 requires platelet activation through P-
selectin  [69, 70] . Hence, blockade of P-selectin or deple-
tion of platelets in hyperlipidemic mice markedly 
reduced CCL5 deposition on arterial endothelium, 
thereby reducing adhesion of monocytes and neutro-
phils  [69, 70] . CCL5 acts through CCR1 and CCR5, both 
of which have been identified to be crucially involved in 
classical monocyte recruitment to sites of atherosclerosis 
 [28, 62] . Of note, heteromers of platelet-derived CXCL4 
and CCL5 have been demonstrated to further amplify 
monocyte adhesion to endothelial cells under flow con-
ditions  [71] . In line, blockade of heteromerization by a 
peptide inhibitor resulted in attenuated monocyte re-
cruitment and reduced atherosclerosis in vivo  [72] .
 Neutrophils Pave the Way for Classical Monocytes in 
Atherosclerosis 
 Neutrophil depletion during early stages of atheroscle-
rosis leads to significantly reduced numbers of inflamma-
tory monocytes as well as macrophages within the arte-
rial wall  [70] . Hence, a partnership between these two leu-
kocyte subsets especially during onset of atherosclerosis 
appears likely. Once adhering to the vessel wall, neutro-
phils release soluble components such as azurocidin, 
which is cationic in nature and therefore  favors immobi-
lization on the endothelium, where it is presented to roll-
ing monocytes and promotes their firm adhesion  [73] . 
This is complemented by the capacity of azurocidin to 
increase expression of adhesion molecules  [74, 75] . Other 
neutrophil-borne antimicrobial peptides described to 
possess monocyte-attracting activity are cathepsin G 
 [76] , cathelicidins (LL37 in humans, CRAMP in mice) 
and defensins  [77] , all of which can be found in plaques 
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 [15, 78] . Cathepsin G and cathelicidins have been de-
scribed to induce chemotactic activity by engagement of 
formyl peptide receptors (FPRs)  [79–81] which are pres-
ent on classical monocytes, whereas human neutrophil 
peptides seem to trigger endothelial and platelet activa-
tion, thereby promoting monocyte adhesion and accu-
mulation  [82] . However, until recently, a conclusive 
mechanism linking neutrophil secretion products and 
monocyte recruitment in atherosclerosis remained elu-
sive. Then it became evident that neutrophil-derived 
CRAMP is responsible for classical monocyte adhesion to 
atherosclerotic endothelium during early stages of lesion 
formation. Hyperlipidemic Apoe -/- mice rendered neu-
tropenic as well as Apoe -/- mice deficient in CRAMP not 
only displayed markedly reduced endothelial and intra-
plaque deposition of CRAMP but were accordingly char-
acterized by decreased luminal adhesion of classical 
monocytes [83]. CRAMP-mediated adhesion of classical 
monocytes was found to be FPR dependent [84]. These 
data clearly indicate a direct link between neutrophil-de-
rived CRAMP and monocyte recruitment in atheroscle-
rosis.
 In addition to the direct monocyte-attracting activity 
of neutrophil secretion products, granule proteins such as 
proteinase 3 can directly activate cells, e.g., endothelial 
cells, to secrete chemokines, thereby promoting recruit-
ment of classical, inflammatory monocytes  [74] . Protein-
ase 3 for example was shown to induce production of 
CCL2 from endothelial cells  [85] . Additionally, CCL6, 
CCL9, CCL15 and CCL23, all of which are macrophage-
derived chemokines, have been described to act as weak 
ligands for CCR1  [74] . Interestingly, their ability to acti-
vate CCR1 on inflammatory monocytes was shown to be 
increased by up to 1,000-fold following exposure to neu-
trophil-derived serine protease  [86] , thus providing an 
alternative mechanism of neutrophil-driven monocyte 
recruitment.
 Yet another mechanism of neutrophil-triggered 
monocyte recruitment is known as IL-6 trans-signaling. 
In this regard, activated or apoptotic neutrophils cause 
the shedding of IL-6Rα; sIL-6Rα then binds to IL-6 re-
leased by macrophages and endothelial cells and via liga-
tion of endothelial gp130 triggers upregulation of CCL2 
and VCAM-1 in endothelial cells leading to increased re-
cruitment of monocytes in conditions of acute inflamma-
tion  [87–89] . The importance of this mechanism in arte-
rial macrophage accumulation was shown in recent stud-
ies  [90–92] . Therein, the authors could show that 
treatment with a fusion protein of the natural IL-6 trans-
signaling inhibitor soluble gp130 dramatically reduced 
atherosclerosis in hypercholesterolemic mice without af-
fecting serum lipid levels. In addition, VCAM-1, a down-
stream effector of the IL-6 trans-signaling pathway is 
known to be critical in arterial monocyte recruitment as 
mice deficient in VCAM-1 display lowered monocyte in-
flux accompanied by reduced lesion sizes  [50] .
 Summary 
 Continuous influx of classical monocytes is indispens-
able in the initiation and progression of atherosclerotic 
plaque development, and blocking recruitment may be a 
promising target to induce plaque regression and en-
hance plaque stability, also during late stages of athero-
sclerosis  [3] . Thus, identification of molecular cues spe-
cifically guiding classical monocytes into atherosclerotic 
lesions is a primary interest in ongoing and future athero-
sclerosis research. Besides adhesion molecules being in-
volved in the traditionally established leukocyte adhesion 
cascade, chemotactic molecules released from activated 
neutrophils and platelets may serve as promising targets 
for future research.
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